Agonist News and Research

RSS

GSK, MD Anderson partner to develop new therapeutic antibodies against cancer

The University of Texas MD Anderson Cancer Center and GlaxoSmithKline (GSK) have signed a research collaboration and license agreement to develop new therapeutic antibodies that promote an immune system attack against cancer.

10 Dec 2012

Drug offers alternative treatment strategy for insomnia

Orexin receptor antagonism may offer a novel treatment approach to insomnia, clinical findings suggest.

7 Dec 2012

Naurex reports positive results from GLYX-13 Phase IIa trial on depression

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13.

6 Dec 2012

LP-211 compound shows promise against Fragile X syndrome

A potential new therapeutic strategy for treating Fragile X syndrome is detailed in a new report appearing in the current issue of Biological Psychiatry, from researchers led by Dr. Lucia Ciranna at University of Catania in Italy.

29 Nov 2012

Rhythm raises additional $8 million to complete Series B financing

Rhythm announced today that the company has raised an additional $8 million to complete a $33 million Series B financing.

27 Nov 2012

Adrenoreceptor shows potential in overactive bladder treatment

Mirabegron, a β3-adrenoreceptor agonist, has shown 12-month safety, tolerability, and persistence of effect in patients with overactive bladders, show study findings.

14 Nov 2012

Taste receptor governs respiratory infection susceptibility

The bitter taste receptor TAS2R38 may play a role in innate defense, say researchers, who have found that variations in the TAS2R38 gene may regulate susceptibility to respiratory infection.

12 Nov 2012

Coffee hastens bowel recovery after colectomy

Individuals undergoing an elective open or laparoscopic colectomy recover bowel function more quickly if they drink coffee than if they drink water after the procedure, indicate the results of a German study.

8 Nov 2012

Low molecular weight agents heighten inhalation challenge risk

Asthmatic reactions needing drug treatment are more likely to result from specific inhalation challenges for occupational asthma with low molecular weight agents than high molecular weight agents, show the results of a Belgian study.

6 Nov 2012

Receptor expression sheds light on nasal polyposis

The increased expression of a leukotriene receptor and a glucocorticoid receptor may contribute to the development of nasal polyposis, report researchers.

6 Nov 2012

TransTech Pharma to complete TTP054 Phase 2 trial on type 2 diabetes

TransTech Pharma, Inc., announced today that recruitment of patients for its recently initiated, multi-center Phase 2 clinical trial of TTP054 in type 2 diabetics, is exceeding expectations with initial top line results available in early 2013. The 90-day proof of concept study is being conducted in type 2 diabetics not well controlled with approved oral anti-diabetic agents.

2 Nov 2012

Additional data from EnVivo’s EVP-6124 Phase 2b trial on AD presented at CTAD meeting

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today presented pharmacokinetic and pharmacodynamic data along with the previously reported statistically significant clinical results from its Phase 2b clinical trial of EVP-6124, a novel alpha-7 agonist, in patients with Alzheimer's disease.

1 Nov 2012

Positive results from Celldex’s CDX-1401 Phase 1 study on solid tumors

Celldex Therapeutics, Inc. today announced positive results demonstrating promising clinical effects in a Phase 1 study of CDX-1401 in solid tumors in combination with the toll-like receptor (TLR) agonists resiquimod and/or Poly ICLC.

30 Oct 2012

Study demonstrates role of IRX4204 in alleviating cognitive decline in animal models of AD

New research presented in October at the 6th Neurodegenerative Conditions Research and Development Conference in San Francisco demonstrates the role of the investigational compound IRX4204 in alleviating cognitive decline in animal models of Alzheimer's disease (AD).

29 Oct 2012

Rhythm presents RM-131 Phase 1 clinical trial results for diabetic gastroparesis at ACG 2012

Rhythm announced today the results of two Phase 1 clinical trials of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis, which demonstrated that RM-131 greatly accelerates gastric emptying in healthy subjects with good tolerability.

22 Oct 2012

Liver x receptor plays an important role in diabetic nephropathy

Researchers have discovered a new therapeutic target for diabetic nephropathy, the leading cause of kidney failure.

19 Oct 2012

Researchers identify brain mechanisms that regulate cocaine-seeking behavior

Researchers from the University of Wisconsin-Milwaukee (UWM) have identified mechanisms in the brain responsible for regulating cocaine-seeking behavior, providing an avenue for drug development that could greatly reduce the high relapse rate in cocaine addiction.

19 Oct 2012